drugset
drugset / Trial / NCT06545097

A Study of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty

NCT06545097 ↗

Phase 3 Completed 279 enrolled Tris Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a Abdominoplasty.

Timeline

Start
2024-09-03
Primary completion
2024-12-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cebranopadol Small molecule 200 ug —
Subject Cebranopadol Small molecule 400 ug —

Indications

No indication recorded.